drugset
drugset / Trial / NCT00068497

Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer

NCT00068497 ↗

Completed 40 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial is studying the side effects of gefitinib in treating patients with metastatic or unresectable head and neck cancer or non-small cell lung cancer. Gefitinib may stop the growth of cancer cells by blocking the enzymes necessary for their growth

Timeline

Start
2003-08
Primary completion
2007-12
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Gefitinib Small molecule — Oral

Indications

adenoid cystic carcinoma carcinoma of lip esthesioneuroblastoma hypopharynx squamous cell carcinoma inverted papilloma larynx verrucous carcinoma lymphoepithelial-like carcinoma medullary thyroid gland carcinoma metastatic squamous cell carcinoma nasal cavity and paranasal sinus lethal midline granuloma nasal cavity and paranasal sinus squamous cell carcinoma nasopharyngeal squamous cell carcinoma non-small cell lung carcinoma oral cavity mucoepidermoid carcinoma oropharynx squamous cell carcinoma parathyroid gland carcinoma poorly differentiated thyroid gland carcinoma salivary gland cancer thyroid gland papillary carcinoma thyroid gland undifferentiated (anaplastic) carcinoma tongue carcinoma undifferentiated carcinoma of nasopharynx verrucous carcinoma of oral cavity